Physician profile
Steven E Balint
NPI 1699770131
$1,918.13
in general payments reported to CMS, 2019-2025
21 companies · $755 in 2025
The $755 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $61.70 · 2021: $94.96 · 2022: $22.91 · 2023: $117 · 2024: $312 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $227.55 | 2019-2025 | Wegovy |
| Abbvie INC. | $213.71 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Intra-Sana Laboratories | $186.40 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Astrazeneca Pharmaceuticals Lp | $184.78 | 2019-2025 | Airsupra, Breztri |
| Pfizer INC. | $145.39 | 2019-2025 | |
| Lilly USA, LLC | $145.25 | 2019-2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $129.46 | 2019-2025 | Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $110.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Fluarix Quadrivalent |
| Janssen Pharmaceuticals, INC | $107.91 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $84.46 | 2019-2021 | |
| Amgen INC. | $66.00 | 2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $57.14 | 2024 | Voquezna |
| Amarin Pharma, INC. | $46.19 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.37 | 2021-2024 | Jardiance |
| Janssen Biotech, INC. | $34.69 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $30.20 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.35 | 2019-2025 | Zoryve |
| Hikma Pharmaceuticals USA | $25.29 | 2019 | |
| Abbott Laboratories | $23.19 | 2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $22.91 | 2022 | |
| Allergan, INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Balint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.